CEL 5000
Alternative Names: CEL-5000Latest Information Update: 29 Apr 2024
Price :
$50 *
At a glance
- Originator CEL-SCI Corporation
- Class Peptide vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Rheumatoid arthritis
Most Recent Events
- 19 Mar 2024 Preclinical trials in Rheumatoid arthritis in USA (Parenteral)
- 18 Sep 2020 CEL-SCI Corporation receives patent protection from the European Patent Office for LEAPS platform technology related to autoimmune diseases including rheumatoid arthritis
- 08 Jun 2018 CEL-SCI has patent protection for LEAPS technology in USA